Why the study?
The relationship between markers of enhanced platelet reactivity and inflammation, and their combined usefulness for risk stratification in STEMI patients, was not clear.
Does the combination of hs-CRP, NLR, and platelet reactivity on arrival predict major adverse cardiovascular events in patients with STEMI?
Does the combination of hs-CRP, NLR, and platelet reactivity on arrival predict major adverse cardiovascular events in patients with STEMI?
Answers are grounded in this paper and cite their sources.
A combination of hs-CRP, NLR, and platelet reactivity measured on arrival can help risk-stratify STEMI patients for recurrent adverse events over 1 year.
BACKGROUND: Patients with ST-elevation myocardial infarction (STEMI) exhibit pro-thrombotic and pro-inflammatory states. Markers of enhanced platelet reactivity and inflammation are predictive of adverse outcome. However, the relationship between these biomarkers, and their combined usefulness for risk stratification, is not clear. METHODS: In a prospective study of 541 patients presenting with STEMI, blood samples were taken on arrival to measure high-sensitivity C-reactive protein (hs-CRP), neutrophil/lymphocyte ratio (NLR) and platelet reactivity using the point-of-care Global Thrombosis Test. These biomarkers, alone and in combination, were related to the occurrence of major adverse cardiovascular events (MACE, defined as composite of cardiovascular death, myocardial infarction and cerebrovascular accident) at 30 days and 12 months. CONCLUSION: A combination of three easy to measure biomarkers on arrival, namely hs-CRP, NLR and platelet reactivity, can help identify STEMI patients at high risk of recurrent adverse events over the subsequent year.
No takes yet. Share an insight, caveat, or question.
Adatia et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: